CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa < sup > ® < /sup > )

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa < sup > ® < /sup > )

Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news